antibiotic
a chemical substance derivable from a mold or bacterium that can kill microorganisms and cure bacterial infections
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
Researched by: Codex + Grok
Purpose and description
Enable an AI agent to recognise an antibiotic, assess evidence of its identity, antibacterial activity and usable state, and identify the conditions and authority required for a proposed use.
A naturally derived or chemically related antibacterial agent, typically a small molecule produced by a mold or bacterium or a semi-synthetic analogue of such a molecule, that at concentrations achievable in a host can kill or inhibit bacteria and is used to treat bacterial infection.
It can be Resolve substance identity and flag uncertain membership under the registry definition.; Retrieve and compare antibacterial measurements while preserving organism and assay context.; Identify gaps between a resistance or susceptibility claim and its supporting evidence.; Assess whether sample potency and integrity evidence support further evaluation or require a hold.; Identify applicable handling conditions for the specified substance form.; Route a proposed therapeutic use to linked product, patient and prescribing models with unresolved constraints attached..
Distinguishing features
Require a defined chemical substance or explicitly characterised substance mixture; a producing organism, mold culture or unspecified extract is not sufficient identification.
Check documented derivation from a mold or bacterium against the registry definition; antibacterial activity alone does not settle membership for wholly synthetic substances.
Require antibacterial evidence linked to an organism and test conditions; an antiviral or antifungal label alone does not establish the relevant activity.
Distinguish evidence of inhibited growth from evidence of bacterial killing when evaluating the registry's wording.
Separate the antibiotic substance from a tablet, injectable preparation or disinfectant product containing it; those products need linked models.
Scope
+ Chemical identity and evidence of derivation from a mold or bacterium
+ Antibacterial activity against identified organisms under specified conditions
+ Mechanism of action and relationships to resistance mechanisms
+ Substance potency, degradation and stability requirements
+ Evidence and constraints relevant to a proposed antibacterial use
- Finished medicinal-product composition, packaging and marketing authorisation
- Manufacturing execution, batch release and supply-chain custody
- Bacterial taxonomy and complete organism or isolate descriptions
- Patient diagnosis, prescribing, dosing and treatment monitoring
- Infection episodes, transmission and population-level stewardship programmes
Characteristics
- Chemical identity
- Preferred substance name, structural identifiers, stereochemistry and specified salt or derivative Prevents evidence for different chemical entities or forms from being treated as interchangeable.
- Derivation relationship
- Linked producing organism, natural precursor and documented transformation route; unresolved where evidence is missing Supports membership decisions under the registry's biological-derivation definition.
- Antibacterial effect
- Growth inhibition, killing, neither demonstrated or unresolved, qualified by organism and assay conditions Keeps different experimental endpoints distinct.
- Minimum inhibitory concentration
- mg/L, with isolate, method, conditions, endpoint and censoring qualifier Records an activity measurement without treating it as an unconditional property of the substance.
- Susceptibility interpretation
- Reported category with organism, applicable standard, version and exposure assumptions; uninterpretable where these are absent Makes the basis and limits of an interpretation inspectable.
- Antibacterial target or process
- Linked molecular target or bacterial process, supported mechanism and confidence Connects activity claims to mechanistic evidence and possible resistance relationships.
- Resistance relationship
- Linked organism or isolate, resistance determinant or phenotype, evidence and observation date Prevents resistance from being recorded as a universal attribute of the antibiotic.
- Assayed potency
- Method-defined activity units per mass or percentage of a specified reference potency Supports assessment of a sample while distinguishing biological activity from chemical purity.
- Chemical integrity
- Within specified limits, outside specified limits or unassessed, with analytical evidence Identifies whether degradation or impurities undermine a proposed use.
- Stability envelope
- Evidence-linked temperature, light, moisture, pH and duration conditions for a specified substance form Supports handling decisions without transferring storage claims between incompatible forms or preparations.
Analytical facets
- substance
- material
- origin
- manufactured
- agency
- inert
- mobility
- portable
- scale
- handheld
- affordances
- graspable, consumable
Also called
+74
Where this came from
oewn:2024 · CC BY 4.0
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 6 bundles · 11 layers · 11 findings · 21 questions.
Identity and biological derivation Establishes which substance is represented and how it relates to the registry's origin-based definition.
An antibacterial name or effect does not by itself resolve chemical identity or the required biological derivation.
Substance identity
Separates the active substance from related chemical forms and preparations.
Defined antibiotic entity
Record the evidence needed to distinguish this antibiotic from synonyms, salts, derivatives and products containing it.
- What chemical structure, stereochemistry or defined mixture establishes the identity behind this name? definition
- Which named forms represent this substance, and which require links to distinct substances or medicinal products? boundary
Biological origin
Examines derivation independently of the route used to manufacture a particular sample.
Documented derivation
Record evidence connecting the substance to a producing microorganism or biologically derived precursor.
- What source documents the producing mold or bacterium, natural precursor or derivation route? provenance
- Does the registry include this substance if its current manufacture is synthetic or it is a modified natural precursor? boundary
Antibacterial activity and interpretation Captures what activity has been demonstrated and the conditions under which it can be interpreted.
Activity must remain tied to the tested organism, method and endpoint to support a defensible assessment.
Experimental activity
Preserves the experimental basis of inhibition and killing claims.
Organism-specific effect
Record antibacterial measurements as contextual evidence rather than an unconditional spectrum label.
- Which organism or isolate was tested, using what method, concentration range, medium and exposure duration? measurement
- Does the measured endpoint establish growth inhibition, bacterial killing or another effect, and what uncertainty accompanies it? measurement
Interpretation limits
Separates measured activity from susceptibility categories and proposed clinical relevance.
Qualified susceptibility claim
Record the rules and assumptions required to interpret an activity result.
- Which interpretive standard and version, if any, apply to this antibiotic, organism and test result? provenance
- What exposure, infection-site or other assumptions limit transfer of this interpretation to a proposed use? boundary
Mechanism and resistance Connects antibacterial action to evidence about how organisms evade or lose susceptibility to it.
An agent needs to distinguish a supported mechanism from a class-based assumption and a resistance signal from demonstrated treatment relevance.
Mechanism of action
Identifies supported targets or bacterial processes involved in activity.
Supported antibacterial mechanism
Record the mechanism claim, its evidence and the limits of extrapolation from related antibiotics.
- Which bacterial target or process is implicated, and what evidence directly supports that relationship for this substance? provenance
- Which parts of the mechanism remain inferred from the antibiotic class rather than established for this substance? boundary
Resistance context
Qualifies resistance claims by organism, determinant, phenotype and evidence.
Evidenced resistance relationship
Record resistance evidence without treating a detected determinant or related-drug result as conclusive by default.
- What phenotypic or mechanistic evidence links this organism or isolate to reduced susceptibility to this antibiotic? provenance
- What additional testing or interpretation is required before using a resistance determinant or cross-resistance claim to constrain a proposed use? action
Potency, integrity and handling Determines whether a specified sample retains the chemical and antibacterial properties required for its intended role.
Correct identity alone cannot establish usable potency or justify handling conditions for a particular substance form.
Sample quality
Links sample-specific analytical and activity evidence to explicit acceptance criteria.
Potency and integrity evidence
Distinguish chemical content, impurities and biological potency when assessing an antibiotic sample.
- What assays establish identity, content, relevant impurities and antibacterial potency for this sample? measurement
- Which reference materials and acceptance criteria support the assessment, and are they applicable to the intended use? provenance
Stability and disposition
Relates exposure history to evidence-supported handling and assessment decisions.
Qualified handling decision
Record whether stability evidence covers the actual form and exposure history of the material.
- What stability evidence covers this chemical form under its recorded temperature, moisture, light and solution conditions? provenance
- Do the exposure history and available assays support continued use, additional testing or a hold pending authorised disposition? action
Use evidence and decision boundaries Connects the substance to proposed uses while keeping product approval and individual treatment decisions in their owning models.
Antibacterial activity and acceptable material quality are insufficient on their own to authorise therapeutic use.
Therapeutic evidence
Distinguishes laboratory activity from evidence relevant to treating bacterial infection.
Supported use context
Record the evidence and linked preparations underlying a proposed therapeutic role.
- What evidence supports the proposed infection-related use beyond laboratory antibacterial activity? provenance
- To which preparation, administration route, population and infection context does that evidence apply? boundary
Action authority
Identifies dependencies and authority needed before a substance-level assessment can support action.
Proposed use handoff
Carry relevant evidence and unresolved constraints into the models responsible for the actual use decision.
- Which linked product and patient assessments must resolve exposure, toxicity, allergy, interactions and other applicable constraints? action
- Which authority may approve the proposed use, and what missing evidence currently prevents that decision? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Kinds and varieties
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- beta-lactam (penicillins, cephalosporins, carbapenems, monobactams)
- macrolide
- tetracycline
- aminoglycoside
- glycopeptide
- fluoroquinolone
- lincosamide
- oxazolidinone
- Which of these kinds and varieties hold for the sense of antibiotic this model covers, and on what evidence? provenance
What the second pass must settle
- Does the registry intend to include semisynthetic derivatives and wholly synthetic antibacterials, or enforce biological derivability as a strict membership boundary?
- Is the definition's reference to killing literal, or does the entry also include substances demonstrated primarily to inhibit bacterial growth?
- What evidence threshold satisfies the definition's claim of curing bacterial infections, particularly for experimental substances?
- At what granularity should salts, stereoisomers, natural mixtures and active derivatives share an identity or link to separate registry entries?
- Which authoritative, versioned sources should govern susceptibility interpretation, potency assessment and therapeutic-use evidence for each represented antibiotic?